Fujifilm India and Vijaya Diagnostic Centre Join Hands to spread awareness on Early Detection of Breast Cancer

 

Kurnool: Fujifilm India Pvt Ltd, a leader in the development and application of imaging and information innovations in healthcare technologies, in partnership with Vijaya Diagnostic Centre, Kurnool, Andhra Pradesh, organized an awareness program on breast cancer and the importance of early detection.

As a part of the collaboration with the Centre, Fujifilm India Pvt Ltd installed its state-of-the-art Amulet Innovality — a highly advanced breast cancer diagnostic machine that has made early detection of breast cancer a reality for women. To further educate and support the cause, the company organized a seminar highlighting the clinical relevance of technology along with addressing the key challenges and solutions in breast imaging with digital mammography.

When it comes to cancer amongst women, the number of breast cancer cases are growing at an enormous rate. According to the ministry of health and family welfare, the incidence of breast cancer is 25.8 per 100,000 women and is expected to rise to 35 per 100,000 women by 2026. Despite the innovations in treatment, the risks associated with breast cancer continues to rise. The biggest reason for this is lack of awareness and ignorance of most patients and reaching the doctor during their last stage of the disease. Understanding the situation at hand, Fujifilm strives to educate people and take the technology across regions of India to save lives.

Commenting on the occasion, Mr. Haruto Iwata, Managing Director, Fujifilm India Pvt. Ltd. said, “As a trusted healthcare provider globally, we are delighted to partner with Vijaya Diagnostic Centre to provide women the access to world-class mammography solutions that have a positive impact on early breast cancer detection. Through this association, we aim to offer superior technological medical facilities that can help save lives and encourage patients to become more engaged in their personal care. Reinforcing our commitment towards being a socially responsible brand, we are determined to offer the highest standards of healthcare solutions and a holistic approach to improving women’s healthcare at an affordable cost in India.”

Mammography is the most powerful breast cancer detection tool. It does not prevent breast cancer but can save lives by finding breast cancers as early as possible. According to a report by WHO, Mammograms have been shown to reduce breast cancer mortality by around 20% in women by early detection.

Mr. Chander Shekhar Sibal, Executive Vice President & Head of Medical Division at Fujifilm India said, “Breast cancer is a leading cause of death amongst women. Many of these deaths can be prevented by early detection, treatment and good palliative care. We at Fujifilm are committed and striving to develop solutions for women that encourage early detection and improve the outcomes for breast cancer screening across the city. We are grateful to associate with Vijaya Diagnostic Centre to sustain our vision and spread awareness about early detection of breast cancer in India.”

Dr. Surender Reddy, Chairman, Vijaya Diagnostic Centre Pvt. Ltd. said, “Our partnership with Fujifilm India will combine the power of innovation and scale to fight against breast cancer in a whole new way. One of the key aspects of curing cancer is early and accurate detection that results in increased survival rates among patients. We look forward to our association with Fujifilm and will continue to strengthen it each year to address such crucial issues like breast cancer.”

Modern-day digital mammography machines with tomosynthesis such as the Fujifilm’s 50 Micron digital Mammography – Amulet Innovality can detect cancer early and involve very little radiation, even less than a standard chest X ray. In the future, digital mammography will become more and more common. Most oncologists agree that breast SCREENING mammography should start at the age of 40 and earlier in patients with high risks like genetic predisposition (BRCA 1 & BRCA 2 antigen positive) and those with strong family history.